How Identity And Brain Mapping Are Changing The Way Companies Advertise
For your business to be successful, people have to know it exists. You may be able to get the company off the ground through word of mouth, but eventually your business will need some well-targeted advertising and marketing.
As the advertising landscape continues to change, it can be difficult for business owners to figure out where to put their ad dollars. Pranav Yadav, CEO of Neuro-Insight, and George Slefo, Tech Reporter at AdAge, discuss the present and future of the advertising industry.
Yadav's company uses neuromarketing to help companies create targeted advertisements that spike brain activity and memory. Yadav explains exactly how they use brain mapping to improve the efficacy of ads.
Slefo takes a look at where the money is going in the advertising industry. According to the International Advertising Bureau, 75 cents of every ad dollar goes to Facebook and Google. Slefo says it's because they have proven time and again to give companies strong returns on investment.
YouTube will offer creators a way to rejoin the streaming platform if they were banned for violating COVID-19 and election misinformation policies that are no longer in effect.
Lukas Alpert of MarketWatch explores how networks, brands, and ad buyers absorb the shockwaves when late‑night show hosts are suddenly cut — and brought back.
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Scott Trench, host of the BiggerPockets Money Podcast, explores how recent rate cuts, high borrowing costs, and mortgage rates are reshaping U.S. real estate.
